The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 12, 2010, Pages 1330-1336

  Orr, D W ^a   Patel, R K ^a   Lea, N C ^a   Westbrook, R H ^a   O'Grady, J G ^a   Heaton, N D ^a   Pagliuca, A ^a   Mufti, G J ^a   Heneghan, M A ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2;

ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC SCREENING; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; LIVER ABSCESS; MALE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POINT MUTATION; POLYMERASE CHAIN REACTION; PORTOSPLENOMESENTERIC VEIN THROMBOSIS; PRIORITY JOURNAL; SEPSIS; THROMBOCYTE COUNT; THROMBOPHILIA; UMBILICAL VEIN; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASE 2; MALE; MESENTERIC VEINS; MIDDLE AGED; MUTATION; PORTAL VEIN; PREVALENCE; SPLENIC VEIN; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 77952751251     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04299.x     Document Type: Article

References (25)

1. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic vein thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000 31 : 587 591.
2. Chawla Y, Duseja A, Dhiman RK. Review article: the modern management of portal vein thrombosis. Aliment Pharmacol Ther 2009 30 : 881 894.
3. Kessler CM. Propensity for haemorhage and thrombosis in chronic myeloproliferative disorders. Semin Haematol 2004 41 : 10 4.
4. Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy - a follow up study of 68 patients. Clin Appl Thromb Hemost 2000 6 : 31 5.
5. Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC. Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol 2000 79 : 312 318.
6. Orr DW, Harrison PM, Devlin J, et al. Chronic mesenteric venous thrombosis: evaluation and determinants of survival during long-term follow-up. Clin Gastroenterol Hepatol 2007 5 : 80 6.
7. Pagliuca A, Mufti GJ, Janossa-Tahernia M, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis - possible evidence of an occult myeloproliferative state. Q J Med 1990 76 : 981 989.
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005 352 : 1779 1790. (Pubitemid 40570926)
9. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005 365 : 1054 1061.
10. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005 434 : 1144 1148. (Pubitemid 40663494)
11. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization of Tumours. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues.
12. Xavier SG, Gadelha T, Pimenta G, et al. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci 2009 Epub ahead of print].
13. Bayraktar Y, Harmanci O, Buyukasik Y, et al. JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci 2008 53 : 2778 2783.
14. Tondeur S, Boutruche S, Biron-Andreani C, Schved JF. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study. Thromb Haemost 2009 101 : 787 789.
15. Goulding C, Uttenthal B, Foroni L, et al. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Hematol 2008 30 : 415 419.
16. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006 44 : 1528 1534.
17. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007 5 : 55 61.
18. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007 110 : 840 846.
19. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005 131 : 208 213.
20. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006 91 : 169 175.
21. Kocher G, Himmelmann A. Portal vein thrombosis (PVT): a study of 20 non-cirrhotic cases. Swiss Med Wkly 2005 135 : 372 376.
22. Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001 120 : 490 497.
23. Percy MJ, Scott LM, Erber WN, et al. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 2007 92 : 1607 1614.
24. Colaizzo D, Amitrano L, Tiscia GL, Grandone E, Guardascione MA, Margaglione M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007 110 : 2768 2769.
25. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006 130 : 2031 2038.